En Es
Categories

Industry News


Greiner Bio-One to Serve Spain and Portugal through Distribution Subsidiaries

By Labmedica International staff writers
28 Mar 2017

Image: Greiner Bio-One will serve customers in Spain and Portugal through its own distribution subsidiaries (Photo courtesy of iStock).Greiner Bio-One has acquired its long-standing distribution partners, VacuetteEspaña and Vacuette Portugal, which will now allow the medical technology company to serve its customers in Spain and Portugal directly through its own distribution subsidiaries.

Greiner Bio-One, a part of the Greiner Group, specializes in the development, production and distribution of high-quality plastic products for laboratory use. The company is a technology partner for hospitals, laboratories, universities, research institutes, the diagnostic and pharmaceutical industry and biotechnology.

For over 20 years, the Greiner Group has worked with VacuetteEspaña, S.A. and Vacuette Portugal Importação e Exportação de Material Hospitalar, S.A., both of which were previously exclusive distributors for Greiner Bio-One International on the Iberian Peninsula. Towards the end of February 2017, Greiner Bio-One entered into official acquisition agreements with both of its distribution partners that came into effect on March 1, 2017. The two subsidiaries in Madrid and Porto will now continue to supply directly to their customers in both the markets.

“Having our own local subsidiaries will bring us closer to our customers and enable us to cater to our markets even more effectively at an international level. The acquisition of VacuetteEspaña and Vacuette Portugal is another key step in our globalization strategy,” said Axel Kühner, Chairman of the Management Board of the Greiner Group.

“Following the establishment of our own distribution subsidiaries in Turkey and Italy last year, the new Greiner Bio-One sites in Spain and Portugal are the next step in systematic implementation of our distribution strategy in Europe,” added Rainer Perneker, CEO of Greiner Bio-One International.

“By attaining greater proximity to customers, we aim to develop the two markets on the Iberian Peninsula in an even more targeted way. The acquisitions mark the continuation of our growth over many years and allow us to step up services and customer care at the local level,” said Manfred Buchberger, CEO of Greiner Bio-One Preanalytics.



E-mail Print
FaceBook Twitter Google+ Linked in

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, laboratories and blood banks. The Bioscience division manufactures products for the biomedical industry, including pipettes, PCR plates, reaction tubes, analyzer cups, and cell separation media
Gold member
More info

More articles about Greiner Bio-One

18 Dec 2018
Greiner Bio-One Launches Tube Holder for Blood Collection
Greiner Bio One International has launched the innovative VACUETTE SAFELINK tube holder with male luer lock that facilitates quick and easy blood collection. The tube offers simple handling and can be used in combination with all medical products that have a standard female luer lock connection, such as winged cannulae.
Read More
25 Jun 2018
Greiner Bio-One Launches New Safety Blood Collection Set
Greiner Bio-One has made a new addition to its range of safety products and now offers its customers an even wider selection of safety blood collection sets with the launch of the VACUETTE SAFETY Winged Set.
Read More

Additional news

06 Dec 2021
IHF to Launch Geneva Centre of Healthcare Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) is preparing to launch the Geneva Centre of Healthcare Leadership for Sustainability (the Centre) in 2022 in response to the need for hospitals and healthcare services to address climate change.
Read More
06 Dec 2021
Global Mammography Market to Reach USD 3.4 Billion in 2028 Due To Increasing Prevalence of Breast Cancer
The global mammography market is expected to reach USD 3.4 billion in 2028, driven by the increasing prevalence of breast cancer across the globe, rising government fund for ongoing research on breast cancer, and increasing public awareness about cancer. The market growth is being fueled further by increasing number of screening programs and campaigns to create awareness about breast cancer, improving healthcare infrastructure and facilities, and technological advancements in breast imaging techniques.
Read More
03 Dec 2021
Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population
The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests by physicians, low price of tests, and awareness about complications of high diabetes levels.
Read More
02 Dec 2021
Roche Completes Acquisition of TIB Molbiol Group
Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
Read More
02 Dec 2021
Siemens Partners with Biotech Company Freenome to Develop Blood Test for Early Breast Cancer Detection
Siemens Healthineers (Erlangen, Germany) and Freenome (South San Francisco, CA, USA) have entered into a collaboration in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Read More
01 Dec 2021
Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing
The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow assay kits, demand growth of point-of-care testing, and rise in adoption of LFA kits due to their advantages over laboratory tests.
Read More
30 Nov 2021
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market to Surpass USD 7.5 Billion by 2025
The global chemiluminescence immunoassay (CLIA) analyzers market is estimated to grow at a CAGR of 6.4% in the forecast period of 2020-2025 to reach USD 7.6 billion by 2025, with the reagents segment anticipated to capture almost three-fourth of the overall CLIA analyzers market and reach USD 5.7 billion by the end of 2025.
Read More
29 Nov 2021
Global Fluoroscopy Equipment Market to Top USD3.5 Billion by 2031 Due to Demand for Multipurpose Imaging Tools
The global fluoroscopy equipment market is projected to grow at a CAGR of 6% from an estimated USD 1.9 billion in 2021 to surpass USD 3.5 billion by the end of 2031, driven by surging applications of fluoroscopy equipment across various medical fields such as cardiology, nephrology, urology, and others.
Read More
25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions